A Phase 2 Study of HB0017 in Psoriasis Patients
ConditionPsoriasis (PsO)
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorHuabo Biopharm Co., Ltd.
About this trial
This study is a randomized, double-blind phase 2 clinical trial aimed at exploring the efficacy, safety, and immunogenicity of HB0017 injection with different dosing regimens in the treatment of moderate to severe plaque psoriasis in subjects
Eligibility criteria
Qualifiers
Male or female subjects aged 18-75 years (inclusive)
Chronic plaque psoriasis (PSO) for at least 6 months prior to the randomization.
Psoriasis Area Severity Index (PASI) >=12 and body surface area (BSA) affected by PSO >=10% and Static Physician Global Assessment (sPGA) score >=3.
Subjects who are suitable for systemic treatment or phototherapy for psoriasis as judged by the investigator
Disqualifiers
Forms of psoriasis other than chronic plaque-type (e.g., pustular, erythrodermic and/or guttate psoriasis) at screening or baseline Drug-induced psoriasis
Ongoing use of prohibited treatments
Any active infection (other than common cold) within 14 days
Serious infection defined as requiring hospitalization or iv anti-infective(s) within 1 month prior to randomization
Trial design
Treatments tested in this trial
- HB0017
- HB0017
- HB0017
Treatment groups
200 Participants
are divided into 3 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov